Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
150%(3 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_3
1
33%
Ph phase_2
2
67%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(2)
Terminated(1)

Detailed Status

Completed2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (66.7%)
Phase 31 (33.3%)

Trials by Status

terminated133%
completed267%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_3

Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia

NCT00748189
completedphase_2

A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia

NCT01563055
completedphase_2

A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia

NCT01808326

Clinical Trials (3)

Showing 3 of 3 trials
NCT00748189Phase 3

Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia

Terminated
NCT01563055Phase 2

A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia

Completed
NCT01808326Phase 2

A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3